Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Studies in technetium chemistry applied to the practice of diagnostic nuclear medicine

Thesis/Dissertation ·
OSTI ID:5672453

The syntheses, characterizations and reactivity studies were performed primarily with /sup 99/Tc, a long lived beta emitting isotope with a half-life of ca. 10/sup 5/ years. The biological distribution studies in rats and dogs were performed with mixtures of /sup 99/Tc and /sup 99m/Tc. Four general classes of technetium complexes were synthesized: (a) technetium(II) and technetium(III) complexes of the general formula (TcD/sub 2/X/sub 2/)/sup 0 +/ where D = bidentate tertiary diphosphines such as bis(diphenylphosphino)ethane (DPPE) or bis(dimethylphosphino)ethane (DMPE), and X = a halogen or pseudohalogen; (b) several compounds represented by the general formula (Tc-L)/sub n/ where L = a bi- or tridentate diphosphonate ligand such as methylenediphosphonate (MDP) (these ligands are commonly used in nuclear medicine bone imaging kits); (c) come oxime-technetium complexes containing ligands such as dimethylglyoxime (DMG) and cycloheptanedionedioxime; (d) a mixed metal (Tc, Sn) hexahalogenato complex of the general formula (H/sub 3/O)/sub 2/(Tc/sub n//sup IV/Sn/sub m/sup IV/Br/sub 6/). It is concluded that: (a) the presence of stannous is not a requirement for a bone-imaging agent; (b) an efficacious radiopharmaceutical can be prepared by a route other than reduction of pertechnetate. It appears that the preparation of Tc-radiopharmaceuticals by substitution, rather than redox, routes holds great promise for the development of new imaging agents. (PSB)

OSTI ID:
5672453
Country of Publication:
United States
Language:
English